Pages that link to "Q38154679"
Jump to navigation
Jump to search
The following pages link to Composite endpoints in trials of type-2 diabetes (Q38154679):
Displaying 16 items.
- Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin (Q36989681) (← links)
- Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis. (Q37257372) (← links)
- Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programme (Q37334002) (← links)
- Sex and age discrepancy of HbA1c and fetal hemoglobin determined by HPLC in a large Chinese Han population (Q38931610) (← links)
- Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease (Q39892657) (← links)
- Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT® trial (Q40966874) (← links)
- Antioxidant strategies in the management of diabetic neuropathy. (Q42180667) (← links)
- Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes. (Q47148933) (← links)
- Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes (Q47182784) (← links)
- Blinded sample size recalculation in clinical trials with binary composite endpoints (Q47296986) (← links)
- Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus (Q47326370) (← links)
- Editorial. SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes? (Q51020788) (← links)
- Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study. (Q55284804) (← links)
- CANadian CAnagliflozin Registry: Effectiveness and Safety of Canagliflozin in the treatment of Type 2 diabetes mellitus in Canadian Clinical Practice (Q58612825) (← links)
- Evaluating glucose-lowering treatment in older people with diabetes: Lessons from the IMPERIUM trial (Q89888252) (← links)
- Achieving the composite end-point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once-weekly dulaglutide in Chinese patients with type 2 diabetes: A post-hoc analysis (Q91409675) (← links)